Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial (English)
- New search for: Hahn, Andrew W.
- Further information on Hahn, Andrew W.:
- https://orcid.org/0000-0002-4153-205X
- New search for: Chahoud, Jad
- New search for: Campbell, Matthew T.
- New search for: Karp, Daniel D.
- New search for: Wang, Jennifer
- New search for: Stephen, Bettzy
- New search for: Tu, Shi-Ming
- New search for: Pettaway, Curtis A.
- New search for: Naing, Aung
- New search for: Hahn, Andrew W.
- Further information on Hahn, Andrew W.:
- https://orcid.org/0000-0002-4153-205X
- New search for: Chahoud, Jad
- New search for: Campbell, Matthew T.
- New search for: Karp, Daniel D.
- New search for: Wang, Jennifer
- New search for: Stephen, Bettzy
- New search for: Tu, Shi-Ming
- New search for: Pettaway, Curtis A.
- New search for: Naing, Aung
In:
Investigational New Drugs
;
39
, 5
; 1405-1410
;
2021
-
ISSN:
- Article (Journal) / Electronic Resource
-
Title:Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial
-
Contributors:Hahn, Andrew W. ( author ) / Chahoud, Jad ( author ) / Campbell, Matthew T. ( author ) / Karp, Daniel D. ( author ) / Wang, Jennifer ( author ) / Stephen, Bettzy ( author ) / Tu, Shi-Ming ( author ) / Pettaway, Curtis A. ( author ) / Naing, Aung ( author )
-
Published in:Investigational New Drugs ; 39, 5 ; 1405-1410
-
Publisher:
- New search for: Springer US
- New search for: Springer Science + Business Media B.V
-
Place of publication:Dordrecht [u.a.]
-
Publication date:2021
-
ISSN:
-
ZDBID:
-
DOI:
-
Type of media:Article (Journal)
-
Type of material:Electronic Resource
-
Language:English
- New search for: 44.40 / 44.40$jPharmazie$jPharmazeutika
- Further information on Basic classification
-
Keywords:
-
Classification:
BKL: 44.40 Pharmazie, Pharmazeutika / 44.40$jPharmazie$jPharmazeutika -
Source:
Table of contents – Volume 39, Issue 5
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 1201
-
FGFR leads to sustained activation of STAT3 to mediate resistance to EGFR-TKIs treatmentSong, Xiaoping / Tang, Wei / Peng, Hui / Qi, Xin / Li, Jing et al. | 2021
- 1213
-
Discovery of MTR-106 as a highly potent G-quadruplex stabilizer for treating BRCA-deficient cancersLi, Meng-Zhu / Meng, Tao / Song, Shan-Shan / Bao, Xu-Bin / Ma, Lan-Ping / Zhang, Ning / Yu, Ting / Zhang, Yong-Liang / Xiong, Bing / Shen, Jing-Kang et al. | 2021
- 1222
-
A novel histone deacetylase inhibitor LT-548-133-1 induces apoptosis by inhibiting HDAC and interfering with microtubule assembly in MCF-7 cellsXue, Jinbing / Wu, Gang / Ejaz, Umer / Akhtar, Fahad / Wan, Xinyu / Zhu, Yong / Geng, Aixing / Chen, Yadong / He, Shuying et al. | 2021
- 1232
-
Cytotoxic and radiosensitising effects of a novel thioredoxin reductase inhibitor in breast cancerAbdullah, Nurul A / Inman, Martyn / Moody, Christopher J. / Storr, Sarah J / Martin, Stewart G et al. | 2021
- 1242
-
Identification of novel inhibitors of GLUT1 by virtual screening and cell-based assaysChen, Xiaotong / Zhao, Yunshuo / Lyu, Sifan / Gao, Guanfei / Gao, Yanfeng / Qi, Yuanming / Du, Jiangfeng et al. | 2021
- 1256
-
Early administration of amatuximab, a chimeric high-affinity anti-mesothelin monoclonal antibody, suppresses liver metastasis of mesothelin-expressing pancreatic cancer cells and enhances gemcitabine sensitivity in a xenograft mouse modelFujii, Yuki / Kamachi, Hirofumi / Matsuzawa, Fumihiko / Mizukami, Tatsuzo / Kobayashi, Nozomi / Fukai, Moto / Taketomi, Akinobu et al. | 2021
- 1267
-
Concomitant inhibition of B7-H3 and PD-L1 expression by a novel and synthetic microRNA delivers potent antitumor activities in colorectal tumor modelsMeng, Fanyi / Chen, Yinshuang / Yang, Man / Zhang, Hongjian / Wang, Weipeng et al. | 2021
- 1275
-
Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I studyOlmedo, María Eugenia / Forster, Martin / Moreno, Victor / López-Criado, María Pilar / Braña, Irene / Flynn, Michael / Doger, Bernard / de Miguel, María / López-Vilariño, José Antonio / Núñez, Rafael et al. | 2021
- 1284
-
A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumorsFalchook, Gerald S. / Peeters, Marc / Rottey, Sylvie / Dirix, Luc Y. / Obermannova, Radka / Cohen, Jonathan E. / Perets, Ruth / Frommer, Ronnie Shapira / Bauer, Todd M. / Wang, Judy S. et al. | 2021
- 1298
-
Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I studyPedersen, Katrina S. / Grierson, Patrick M. / Picus, Joel / Lockhart, A. Craig / Roth, Bruce J. / Liu, Jingxia / Morton, Ashley / Chan, Emily / Huffman, Jesse / Liang, Chris et al. | 2021
- 1306
-
Effect of severe renal impairment on the pharmacokinetics of brigatinibGupta, Neeraj / Hanley, Michael J. / Kerstein, David / Tugnait, Meera / Narasimhan, Narayana / Marbury, Thomas C. / Venkatakrishnan, Karthik et al. | 2021
- 1315
-
Phase I first-in-human study of HLX07, a novel and improved recombinant anti-EGFR humanized monoclonal antibody, in patients with advanced solid cancersHou, Ming-Mo / Ho, Ching-Liang / Lin, Hsuan-Yu / Zhu, Yunting / Zhang, Xiaodi et al. | 2021
- 1324
-
A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrationsPiha-Paul, Sarina A. / Azaro, Analía / Arkenau, Hendrik Tobias / Oh, Do-Youn / Galsky, Matthew D. / Pal, Sumanta Kumar / Hamada, Kensuke / He, Yaohua / Yamamiya, Ikuo / Benhadji, Karim A et al. | 2021
- 1335
-
A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancerJeong, Hyehyun / Hong, Yong Sang / Kim, Jeong Eun / Lim, Hyeong-Seok / Ahn, Joong Bae / Shin, Sang Joon / Park, Young Suk / Kim, Seung Tae / Han, Sae-Won / Kim, Tae-You et al. | 2021
- 1348
-
First-in-human evaluation of the novel mitochondrial complex I inhibitor ASP4132 for treatment of cancerJanku, Filip / LoRusso, Patricia / Mansfield, Aaron S. / Nanda, Rita / Spira, Alexander / Wang, Tianli / Melhem-Bertrandt, Amal / Sugg, Jennifer / Ball, Howard A. et al. | 2021
- 1357
-
Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi‐arm phase Ib studyThein, Kyaw Zin / Piha-Paul, Sarina A. / Tsimberidou, Apostolia / Karp, Daniel D. / Janku, Filip / Zarifa, Abdulrazzak / Shah, Jatin / Milton, Denái R. / Bean, Stacie / McQuinn, Lacey et al. | 2021
- 1366
-
Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutationsLee, Jii Bum / Jung, Minkyu / Beom, Seung Hoon / Kim, Gun Min / Kim, Hye Ryun / Choi, Hye Jin / Sohn, Joo Hyuk / Ahn, Joong Bae / Rha, Sun Young / Chung, Hyun Cheol et al. | 2021
- 1375
-
A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinomaChan, Stephen L. / Cheng, Paul N.M. / Liu, Angela M. / Chan, Landon L. / Li, Leung / Chu, Cheuk M. / Chong, Charing C.N. / Lau, Yat M. / Yeo, Winnie / Ng, Kelvin K.C. et al. | 2021
- 1383
-
The clinical efficiency of TACE combined with simultaneous computed tomography‐guided radiofrequency ablation for advanced hepatocellular carcinomaYuan, Peng / Wang, Fei / Zhu, Guangyu / Chen, Baoan et al. | 2021
- 1389
-
The drug lag issue: a 20-year review of ChinaLi, Xiaoyu / Yang, Yue et al. | 2021
- 1399
-
Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancerInoue, Hiroto / Todaka, Akiko / Yamazaki, Kentaro / Fushiki, Kunihiro / Shirasu, Hiromichi / Kawakami, Takeshi / Tsushima, Takahiro / Hamauchi, Satoshi / Yokota, Tomoya / Machida, Nozomu et al. | 2021
- 1405
-
Pembrolizumab for advanced penile cancer: a case series from a phase II basket trialHahn, Andrew W. / Chahoud, Jad / Campbell, Matthew T. / Karp, Daniel D. / Wang, Jennifer / Stephen, Bettzy / Tu, Shi-Ming / Pettaway, Curtis A. / Naing, Aung et al. | 2021
- 1411
-
Combined immunotherapy and targeted treatment for primary alveolar soft part sarcoma of the lung: case report and literature reviewSu, Hui / Yu, Chao / Ma, Xuezhen / Song, Qingcui et al. | 2021
- 1419
-
Icotinib, an effective treatment option for patients with lung adenocarcinoma harboring compound EGFR L858R and A871G mutationJin, Lin-ling / Wu, Zhen-zhen / Wang, Yan-li / Chen, Dong-sheng / Li, Si / Xiao, Mingzhe / Zhao, Xin et al. | 2021
- 1422
-
Pharmacokinetics of the oral multikinase inhibitor regorafenib and its association with real‐world treatment outcomesFukudo, Masahide / Asai, Keiko / Tani, Chikayoshi / Miyamoto, Masashi / Ando, Katsuyoshi / Ueno, Nobuhiro et al. | 2021
- 1432
-
Successful treatment of an adult patient with diffuse midline glioma employing olaparib combined with bevacizumabWang, Yong / Xu, Jun / Luo, Ningning / Qi, Chuang / Tao, Rongjie et al. | 2021
- 1436
-
Helicobacter pylori infection as a potential favorable factor for immune checkpoint inhibitor therapy for gastric cancerZhang, Ming-jun / Chen, Dong-sheng / Li, Si / Chen, Lin / Qi, Ying-xue / Zhang, Cong-jun et al. | 2021
- 1439
-
Identification of CDC20 as an immune infiltration-correlated prognostic biomarker in hepatocellular carcinomaXiong, Chen / Wang, Zhihuai / Wang, Guifu / Zhang, Chi / Jin, Shengjie / Jiang, Guoqing / Bai, Dousheng et al. | 2021
- 1454
-
Comment on “Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma”Lin, Jiong et al. | 2021
- 1456
-
Author Correction to: Advances in anti-BRAF therapies for lung cancerRoviello, Giandomenico / D’Angelo, Alberto / Sirico, Marianna / Pittacolo, Matteo / Conter, Felipe Umpierre / Sobhani, Navid et al. | 2021